ProfileGDS5678 / 1430218_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 39% 39% 39% 36% 39% 40% 42% 38% 39% 39% 39% 38% 38% 39% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 12.9228139
GSM967853U87-EV human glioblastoma xenograft - Control 22.8977439
GSM967854U87-EV human glioblastoma xenograft - Control 32.8925439
GSM967855U87-EV human glioblastoma xenograft - Control 42.7792236
GSM967856U87-EV human glioblastoma xenograft - Control 52.8469739
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.0036640
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 23.0393942
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 32.8604838
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 42.8767639
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 12.8849939
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 22.8832739
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 32.8403838
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 42.8824538
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 52.8854739